Details of the Drug

General Information of Drug (ID: DMDNJP5)

Drug Name
NM21-1480
Indication
Disease Entry ICD 11 Status REF
Advanced solid tumour 2A00-2F9Z Phase 1/2 [1]
Non-small-cell lung cancer 2C25 Phase 1/2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DUVH60
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Co-stimulatory molecule 4-1BB (CD137) TTPW9LJ TNR9_HUMAN Modulator [2]
Programmed cell death 1 ligand 1 (PD-L1) TT8ZLTI PD1L1_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Advanced solid tumour
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death 1 ligand 1 (PD-L1) DTT CD274 4.38E-07 0.37 2.1
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04442126) A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Numab Therapeutics.